Business Wire

IVI RMA To Acquire North American Operations of Eugin Group, Including Boston IVF, Creating a Leading North American Fertility Group

8.11.2023 08:46:00 CET | Business Wire | Press Release

Share

IVI RMA, one of the largest reproductive medicine groups in the world, has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius. The strategic additions will grow IVI RMA to become a leading fertility group in North America and reinforce the company’s commitment to providing evidence-based fertility solutions with the greatest chance of success to the greatest number of patients.

“We are thrilled to welcome Boston IVF, its partner clinics and TRIO to the IVI RMA network as we continue to bring the best fertility science to more markets across North America,” said Javier Sanchez Prieto, CEO of IVI RMA. “We are confident that our shared vision and complementary strengths make this partnership greater than the sum of its parts. Our ethos of compassionate, personalized care will help ensure we deliver a world-class patient experience and successful outcomes for more patients.”

The acquisition will add over 600 employees across 13 labs and 32 satellite offices to IVI RMA’s network of 10 labs and 29 satellites in North America, bringing the organization’s total headcount to more than 4,400 globally. In addition, Boston IVF brings multiple academic affiliations, including Harvard Medical School, Dartmouth Hitchcock Medical School, Boston University Medical Center, and Tufts Medical Center, among others. The acquired businesses will continue to operate under their existing brands.

“These highly-respected fertility brands joining the IVI RMA family is a major milestone for our business and a huge positive for the patients we serve,” added Lynn Mason, CEO of IVI RMA America. “We are just getting started and want to continue our growth by joining forces with physicians and organizations like Boston IVF that share the cultural and medical vision of the U.S. medical leadership of IVI RMA. Our team is excited about the opportunities to learn from each other and grow stronger together while building a great culture and workplace for our employees.”

“IVI RMA has a reputation for delivering the best outcomes for patients, backed by three decades of scientific research from some of the world’s leading fertility experts,” said David Stern, CEO of Boston IVF. “We and our colleagues at TRIO are excited to join this strong global network so that our patients will continue to benefit from the best science in the industry. In addition, we look forward to operational enhancements, including best-in-class electronic medical records technology and a prosperous partnership as we continue to grow in North America as part of IVI RMA.”

About IVI RMA Global

IVI RMA is one of the world's leading Reproductive Medicine groups. It is committed to providing evidence-based fertility solutions with the greatest chance of success in the shortest time necessary to patients seeking treatment anywhere in the world. IVI RMA employs more than 4,400 people across +150 locations in 14 countries. The group maintains a team of highly trained physicians as well as renowned scientists and researchers, aligned with its vision of pioneering in the field of Reproductive Medicine.

Learn more at rmanetwork.com and ivirma.com.

About Boston IVF

Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation's first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous "firsts" in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.

About TRIO

TRIO is Canada's leading fertility clinic with 10 locations across Ontario and more than 40 years of experience. TRIO is proud to have the largest in-house fertility medical team in Canada with 13 fertility specialists and over 45 supporting medical staff.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S. Media Contact
Alex Varney
avarney@stantonprm.com
+1 (646) 502-3565

EU Media Contact
Alejandra Moore
amoore@grupoalbion.com
+34 91 531 23 88

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

South African Agency Boundless Delivers Mazda’s First AI-produced Commercial Using Luma Agents15.4.2026 21:07:00 CEST | Press Release

Luma AI today announced that Boundless, an independent creative agency based in Johannesburg, South Africa, has produced Mazda’s first AI-produced commercial using Luma Agents, Luma’s AI-powered creative workflow system. Delivered in less than two weeks from initial brief to final approval, the project marks a significant step in the use of AI-native workflows for commercial production. As part of the collaboration, Boundless has also signed an agreement with Luma to integrate the company’s AI technologies into its creative workflow across future client work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415098939/en/ The project marks a milestone for both Boundless and the broader advertising industry, demonstrating how AI-native workflows can help agencies compress production timelines while maintaining creative quality, brand consistency, and operational oversight. The campaign supports the re-entry of the Mazda MX-5

Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release

The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta

Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release

The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta

New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release

Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres

New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release

Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye